clinical trial · NCT05310071
A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease
Biogen·phase3·terminated·n = 1,027
Alzheimer's DiseaseAducanumabPlacebo
brief summary
The primary objective of this study is to verify the clinical benefit of monthly doses of aducanumab in slowing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) score as compared with placebo in participants with early Alzheimer's disease.
started
Jun 2, 2022
primary completion
Aug 12, 2024
completion
Aug 12, 2024
last updated
Apr 23, 2025
official title
A Phase 3b/4 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Verify the Clinical Benefit of Aducanumab (BIIB037) in Participants With Alzheimer's Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol